Cassava Sciences Inc vs Opendoor Technologies Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Opendoor Technologies Inc trades at $2.32 (market cap $2.22B). The key difference: Opendoor Technologies Inc is far larger — about 56.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 28,705,892). Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Opendoor Technologies Inc for 33 Days on average.
| FLNA | OPEN | |
|---|---|---|
Market Cap | $39.40M | $2.22B |
Volume | 759,018 | 28,705,892 |
Sector | Health | Real Estate |
52-Week High | $4.64 | $9.37 |
52-Week Low | $0.68 | $2.27 |
Typical Hold Time | 37 Days | 33 Days |
Enterprise Value | -$43.28M | $3.29B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
Opendoor Technologies (OPEN) trades at $2.27, showing no change in the latest session. The stock faces significant fundamental challenges with a net income margin of -46.74% and negative ROE of -196.89%, though it maintains a reasonable P/S ratio of 0.62. Recent earnings show mixed results with one beat and two misses in the last three quarters. Technical indicators signal bearish momentum with moving averages and oscillators in sell territory, while analyst sentiment remains cautious with 65% hold ratings despite a $4.92 consensus price target representing 117% upside potential.
The outlook remains challenging as the company navigates persistent losses and housing market volatility. While the mortgage expansion initiative and share repurchase program offer potential catalysts, execution risks and macroeconomic headwinds pose significant threats. The substantial gap between current price and analyst targets suggests potential upside if operational improvements materialize, but investors face substantial risk given the company's negative profitability and high debt levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
Read more on OPEN →